FDA grants De Novo authorization to Avulux precision light-filtering lenses for migraine-associated light sensitivity
核心洞察
The FDA granted De Novo marketing authorization to Avulux (搜索) lenses, the first and only FDA-authorized precision optical filter for migraine (搜索)-associated light sensitivity (搜索).
The lenses are indicated to decrease light sensitivity (搜索) in patients aged 12 years or older with episodic migraine (搜索), filtering light at 480 nm and 590 nm wavelengths.
Avulux (搜索) lenses are intended to complement, not replace, a patient's existing migraine (搜索) care, including prescribed medications.
The U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization to Avulux (搜索) for its precision light-filtering lenses designed to decrease light sensitivity (搜索) in patients with migraine (搜索). The authorization establishes Avulux as the first and only FDA De Novo-authorized precision optical filter, marking a regulatory milestone for a device category with no legally marketed predicate device.
The lenses are indicated to decrease the impact of light sensitivity (搜索) in patients aged 12 years or older diagnosed with episodic migraine (搜索). Specifically, the lenses filter light at 480 nm (the high blue range) and 590 nm (the red/amber range), while still allowing light in the remaining visible color spectrum to pass through.
Regulatory pathway and classification
The FDA uses De Novo marketing authorization to regulate devices "for which there is no legally marketed predicate device." Prior to this authorization, Avulux (搜索) lenses were marketed as a general wellness device, according to Charles Posternack, MD, president, CEO and cofounder of Avulux. With the authorization, the lenses can now be marketed as indicated for migraine (搜索)-associated light sensitivity (搜索).
"FDA's de novo authorization classifies Avulux (搜索) into class I, under the generic name 'light attenuation lenses for migraine (搜索)-associated light sensitivity (搜索),' a newly established device category," Posternack said. "The classification defines how Avulux may be used and gives patients, eye care providers, healthcare providers and commercial partners a clear way to understand what Avulux is and who it can help."
The De Novo authorization differs from a 510(k) clearance, which relies on demonstrating "substantial equivalence" to an existing medical device. Because Avulux (搜索) is a first-of-its-kind device, the De Novo pathway was required to establish a new generic device type with its own category and product code.
Supporting clinical evidence
According to Avulux (搜索), the FDA based the authorization on a randomized double-masked trial of 78 participants published in 2023, as well as an experimental study of 16 healthy adults presented at the Association for Research in Vision and Ophthalmology meeting in 2025.
The underlying technology grew out of a neuro-ophthalmologist's years of research into a precision lens technology developed and patented at the University of Utah's Moran Eye Center. Avulux (搜索) was launched in 2018, and the company's approach is grounded in research on how certain visible light wavelengths activate intrinsically photosensitive retinal ganglion cells (ipRGCs).
Intended use and clinical guidance
Avulux (搜索) emphasizes that its glasses are intended to complement, not replace, a patient's usual migraine (搜索) care. The lenses should be used "alongside a patient's existing care, not in place of it," including any medications, Posternack told Healio. Patients diagnosed with episodic migraine are advised to continue their prescribed treatment, including medication.
The lenses can be made with or without a vision prescription, and are intended to be worn like ordinary eyeglasses. The lens technology is embedded in readers, prescription, and non-prescription glasses custom-made and tailored to a wearer's lifestyle, with various frame shape options. The lenses are precision-tinted, hard-coated, and anti-scratch, and are available in a variety of styles, including models that fit over a patient's current frames.
Availability and market presence
Avulux (搜索) lenses are available through the company's website and select eye care providers. The company noted that Avulux has already been dispensed to over 50,000 wearers across North America. The lenses are also available for purchase through select eyecare providers and optical retailers in Australia, New Zealand, and the United Kingdom. In the United States, the lenses are FSA- and HSA-eligible.
Last year, Avulux (搜索) was added to the FDA-funded Consortium for Technology & Innovation in Pediatrics (CTIP). In recent months, the company expanded its lens portfolio with two new options that can be embedded in Avulux frames: Avulux Adapt photochromic lenses and Avulux Atlas polarized lenses.